Biotechnology
Build Your Comparison
Side-by-side financial analysisStock Comparison
ABVX vs DBVT vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Beverages - Non-Alcoholic
ABVX vs DBVT vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||
|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Beverages - Non-Alcoholic |
| Market Cap | $6.61B | $979M | $355.22B |
| Revenue (TTM) | $0.00 | $0.00 | $49.28B |
| Net Income (TTM) | $-427M | $-168M | $13.70B |
| Gross Margin | — | — | 61.7% |
| Operating Margin | — | — | 29.3% |
| Forward P/E | — | — | 25.2x |
| Total Debt | $32M | $22M | $45.49B |
| Cash & Equiv. | $516M | $194M | $10.27B |
ABVX vs DBVT vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Oct 23 | Jun 26 | Return |
|---|---|---|---|
| Abivax S.A. (ABVX) | 100 | 1049.5 | +949.5% |
| DBV Technologies S.… (DBVT) | 100 | 172.4 | +72.4% |
| The Coca-Cola Compa… (KO) | 100 | 146.3 | +46.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ABVX vs DBVT vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ABVX is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.02
- 11.2% 10Y total return vs KO's 120.9%
- Lower volatility, beta 1.02, Low D/E 7.1%, current ratio 8.75x
DBVT plays a supporting role in this comparison — it may shine differently against other peers.
KO carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 1.9%, EPS growth 23.6%, 3Y rev CAGR 3.7%
- 1.9% revenue growth vs DBVT's -100.0%
- 27.8% margin vs ABVX's -3.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 1.9% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 27.8% margin vs ABVX's -3.9% | |
| Stability / Safety | Beta 1.02 vs DBVT's 1.21, lower leverage | |
| Dividends | 2.5% yield; 56-year raise streak; the other 2 pay no meaningful dividend | |
| Momentum (1Y) | +12.6% vs KO's +17.4% | |
| Efficiency (ROA) | 13.1% ROA vs ABVX's -143.2% |
ABVX vs DBVT vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
ABVX vs DBVT vs KO — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KO and DBVT operate at a comparable scale, with $49.3B and $0 in trailing revenue.
| Metric | |||
|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $49.3B |
| EBITDAEarnings before interest/tax | -$327M | -$112M | $15.5B |
| Net IncomeAfter-tax profit | -$427M | -$168M | $13.7B |
| Free Cash FlowCash after capex | -$250M | -$151M | $12.6B |
| Gross MarginGross profit ÷ Revenue | — | — | +61.7% |
| Operating MarginEBIT ÷ Revenue | — | — | +29.3% |
| Net MarginNet income ÷ Revenue | — | — | +27.8% |
| FCF MarginFCF ÷ Revenue | — | — | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -40.0% | +91.5% | +18.2% |
Valuation Metrics
Evenly matched — ABVX and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | |||
|---|---|---|---|
| Market CapShares × price | $6.6B | $979M | $355.2B |
| Enterprise ValueMkt cap + debt − cash | $6.1B | $806M | $390.4B |
| Trailing P/EPrice ÷ TTM EPS | -18.79x | -0.63x | 27.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 25.24x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.43x |
| EV / EBITDAEnterprise value multiple | — | — | 26.36x |
| Price / SalesMarket cap ÷ Revenue | — | — | 7.41x |
| Price / BookPrice ÷ Book value/share | 13.35x | 0.55x | 10.39x |
| Price / FCFMarket cap ÷ FCF | — | — | 67.07x |
Profitability & Efficiency
KO leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-3 for ABVX. ABVX carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs ABVX's 3/9, reflecting strong financial health.
| Metric | |||
|---|---|---|---|
| ROE (TTM)Return on equity | -3.0% | -130.2% | +41.1% |
| ROA (TTM)Return on assets | -143.2% | -89.0% | +13.1% |
| ROICReturn on invested capital | — | — | +15.8% |
| ROCEReturn on capital employed | -77.7% | -145.7% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 | 7 |
| Debt / EquityFinancial leverage | 0.07x | 0.13x | 1.33x |
| Net DebtTotal debt minus cash | -$484M | -$172M | $35.2B |
| Cash & Equiv.Liquid assets | $516M | $194M | $10.3B |
| Total DebtShort + long-term debt | $32M | $22M | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | -14.16x | -189.82x | 10.70x |
Total Returns (Dividends Reinvested)
ABVX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ABVX five years ago would be worth $121,530 today (with dividends reinvested), compared to $2,707 for DBVT. Over the past 12 months, ABVX leads with a +1259.4% total return vs KO's +17.4%. The 3-year compound annual growth rate (CAGR) favors ABVX at 129.9% vs DBVT's -4.0% — a key indicator of consistent wealth creation.
| Metric | |||
|---|---|---|---|
| YTD ReturnYear-to-date | -24.6% | -13.2% | +20.2% |
| 1-Year ReturnPast 12 months | +1259.4% | +89.7% | +17.4% |
| 3-Year ReturnCumulative with dividends | +1115.3% | -11.6% | +46.9% |
| 5-Year ReturnCumulative with dividends | +1115.3% | -72.9% | +63.6% |
| 10-Year ReturnCumulative with dividends | +1115.3% | -89.2% | +120.9% |
| CAGR (3Y)Annualised 3-year return | +129.9% | -4.0% | +13.7% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.15 beta — it tends to amplify market swings less than DBVT's 1.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.2% from its 52-week high vs DBVT's 63.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.05x | 1.14x | -0.20x |
| 52-Week HighHighest price in past year | $148.83 | $26.18 | $84.04 |
| 52-Week LowLowest price in past year | $5.69 | $8.50 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +67.8% | +63.2% | +98.2% |
| RSI (14)Momentum oscillator 0–100 | 41.9 | 26.5 | 65.7 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 210K | 12.6M |
Analyst Outlook
KO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ABVX as "Buy", DBVT as "Buy", KO as "Buy". Consensus price targets imply 180.1% upside for DBVT (target: $46) vs 4.6% for KO (target: $86). KO is the only dividend payer here at 2.47% yield — a key consideration for income-focused portfolios.
| Metric | |||
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $131.22 | $46.33 | $86.29 |
| # AnalystsCovering analysts | 12 | 15 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | +2.5% |
| Dividend StreakConsecutive years of raises | — | 0 | 56 |
| Dividend / ShareAnnual DPS | — | — | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.2% |
KO leads in 3 of 6 categories (Profitability & Efficiency, Risk & Volatility). DBVT leads in 1 (Income & Cash Flow). 1 tied.
ABVX vs DBVT vs KO: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ABVX or DBVT or KO a better buy right now?
The Coca-Cola Company (KO) offers the better valuation at 27.
1x trailing P/E (25. 2x forward), making it the more compelling value choice. Analysts rate Abivax S. A. (ABVX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ABVX or DBVT or KO?
Over the past 5 years, Abivax S.
A. (ABVX) delivered a total return of +1115%, compared to -72. 9% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ABVX returned +1063% versus DBVT's -88. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ABVX or DBVT or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus DBV Technologies S. A. 's 1. 14β — meaning DBVT is approximately -667% more volatile than KO relative to the S&P 500. On balance sheet safety, Abivax S. A. (ABVX) carries a lower debt/equity ratio of 7% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
04Which is growing faster — ABVX or DBVT or KO?
On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23.
6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ABVX or DBVT or KO?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — KO leads at 61. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ABVX or DBVT or KO more undervalued right now?
Analyst consensus price targets imply the most upside for DBVT: 180.
1% to $46. 33.
07Which pays a better dividend — ABVX or DBVT or KO?
In this comparison, KO (2.
5% yield) pays a dividend. ABVX, DBVT do not pay a meaningful dividend and should not be held primarily for income.
08Is ABVX or DBVT or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, DBVT: -88. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ABVX and DBVT and KO?
These companies operate in different sectors (ABVX (Healthcare) and DBVT (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
KO pays a dividend while ABVX, DBVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.